Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?

PubWeight™: 0.93‹?›

🔗 View Article (PMC 1797968)

Published in Ann Rheum Dis on June 23, 2005

Authors

M D Smith1, D Baeten, A-K Ulfgren, I B McInnes, O Fitzgerald, B Bresnihan, P P Tak, D Veale, OMERACT synovial special interests group

Author Affiliations

1: Rheumatology Research Unit, Repatriation General Hospital, Adelaide, South Australia. malcolm.smith@rgh.sa.gov.au

Articles cited by this

The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96

Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol (1997) 2.43

Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 2.37

Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther (2003) 2.26

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25

Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum (1997) 2.12

Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum (1988) 1.85

Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum (2003) 1.82

Variability in cytokine and cell adhesion molecule staining in arthroscopic synovial biopsies: quantification using color video image analysis. J Rheumatol (1997) 1.77

Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) (2000) 1.76

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum (2004) 1.73

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70

Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum (2002) 1.67

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum (2000) 1.62

Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther (2005) 1.52

Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum (2000) 1.49

Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol (1998) 1.47

Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47

Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann Rheum Dis (1994) 1.44

Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.43

Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol (1998) 1.38

The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.36

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis (2001) 1.35

Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis (2001) 1.34

Microscopic measurement of synovial membrane inflammation in rheumatoid arthritis: proposals for the evaluation of tissue samples by quantitative analysis. Br J Rheumatol (1998) 1.32

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum (2004) 1.29

Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis Rheum (1998) 1.29

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 1.28

Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol (1999) 1.23

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol (1999) 1.22

Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther (2005) 1.21

Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis (2001) 1.18

Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. Ann Rheum Dis (1999) 1.17

Microscopic measurement of cellular infiltration in the rheumatoid arthritis synovial membrane: a comparison of semiquantitative and quantitative analysis. Br J Rheumatol (1998) 1.13

In vivo analysis of disease modifying drug therapy activity in rheumatoid arthritis by sequential immunohistological analysis of synovial membrane interleukin 1 beta. J Rheumatol (1994) 1.13

Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum (2004) 1.12

Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies. Rheumatology (Oxford) (2001) 1.11

Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis. Arthritis Rheum (1989) 1.09

An investigation of the action of disease modifying antirheumatic drugs on the rheumatoid synovial membrane: reduction in T lymphocyte subpopulations and HLA-DP and DQ antigen expression after gold or penicillamine therapy. Ann Rheum Dis (1987) 1.07

Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis. J Rheumatol (1999) 1.05

Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum (2003) 1.05

Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Arthritis Rheum (1996) 1.03

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis (2004) 1.03

Immunologic intervention in the pathogenesis of osteoarthritis. Arthritis Rheum (2003) 1.01

Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis (2004) 1.00

Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol (2008) 0.98

Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol (1997) 0.97

Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol (1991) 0.94

Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction. J Rheumatol (2004) 0.93

Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis (2004) 0.92

Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. Rheumatology (Oxford) (2001) 0.83

Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. J Rheumatol (2003) 0.81

Analysis of synovial biopsy samples: opportunities and challenges. Ann Rheum Dis (2000) 0.81

Articles by these authors

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82

Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. J Clin Invest (1977) 5.09

Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol (1996) 3.63

Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis (2005) 3.25

Diffusion relations of urea, inulin and chloride in some mammalian tissues. J Physiol (1942) 2.97

Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum (1996) 2.77

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74

A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest (1999) 2.65

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis (2009) 2.61

A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) (2003) 2.56

High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum (2002) 2.45

Side effects of nasal continuous positive airway pressure in sleep apnea syndrome. Study of 193 patients in two French sleep centers. Chest (1995) 2.45

Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers. Arthritis Rheum (1998) 2.41

Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med (1998) 2.40

The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum (2000) 2.40

Discharges from the sensory organs of the cat's vibrissae and the modification in their activity by ions. J Physiol (1940) 2.39

Natural evolution of moderate sleep apnoea syndrome: significant progression over a mean of 17 months. Thorax (1997) 2.37

Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 2.37

Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol (2014) 2.28

Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis (2008) 2.27

Citrullination is an inflammation-dependent process. Ann Rheum Dis (2006) 2.25

Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum (1998) 2.24

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 2.22

Ultrasound guided injection of recalcitrant plantar fasciitis. Ann Rheum Dis (1998) 2.17

Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum (2000) 2.14

Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol (1994) 2.13

Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis (1978) 2.12

Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis (2002) 2.11

Development of a Cosmetic Procedure Screening Questionnaire (COPS) for Body Dysmorphic Disorder. J Plast Reconstr Aesthet Surg (2011) 2.10

Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med (1988) 2.09

Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol (1992) 2.08

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis (2009) 1.95

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum (2011) 1.86

Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85

Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum (1988) 1.85

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.84

Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83

Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) (2003) 1.83

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum (2011) 1.83

Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol (1998) 1.81

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum (2000) 1.79

Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods (2011) 1.78

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76

Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) (2000) 1.76

Comparison of the accuracy of steroid placement with clinical outcome in patients with shoulder symptoms. Ann Rheum Dis (1997) 1.74

Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis (2003) 1.73

Differential diagnosis of calf pain with musculoskeletal ultrasound imaging. Ann Rheum Dis (2004) 1.73

A role for IL-18 in neutrophil activation. J Immunol (2001) 1.72

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis (2009) 1.72

Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis (2010) 1.71

Ultrasonography in the diagnosis and management of psoriatic dactylitis. J Rheumatol (1999) 1.71

Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis (2008) 1.70

Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis (1994) 1.69

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis (2007) 1.68

Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis (2005) 1.66

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65

Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum (1993) 1.64

High prevalence and persistence of sleep apnoea in patients referred for acute left ventricular failure and medically treated over 2 months. Eur Heart J (1999) 1.63

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis (2007) 1.63

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum (2000) 1.62

Serum lipid levels in Sjögren's syndrome. Rheumatology (Oxford) (2005) 1.59

Brain reactivity of lymphocytotoxic antibodies in systemic lupus erythematosus with and without cerebral involvement. Clin Exp Immunol (1977) 1.57

Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) (2003) 1.56

Evaluation of autoCPAP devices in home treatment of sleep apnea/hypopnea syndrome. Sleep Med (2007) 1.55

An antineuronal antibody cross-reacting with erythrocytes and lymphocytes in systemic lupus erythematosus. Arthritis Rheum (1979) 1.54

Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol (2001) 1.50

Reduction of peripheral blood lymphocytes in patients receiving gold therapy for rheumatoid arthritis. Ann Rheum Dis (1985) 1.49

Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients. Am Rev Respir Dis (1992) 1.49

The diagnosis of iron deficiency in patients with rheumatoid arthritis and anemia: an algorithm using simple laboratory measures. J Rheumatol (1996) 1.46

Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol (2000) 1.45

Validated measurement of periarticular bone mineral density at the knee joint by dual energy x ray absorptiometry. Ann Rheum Dis (2001) 1.45

Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) (2007) 1.43

Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.43

The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol (2000) 1.43

Detection of bacterial DNA in serial synovial samples obtained during antibiotic treatment from patients with septic arthritis. Arthritis Rheum (1999) 1.42

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) (2002) 1.41

Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis (2006) 1.39

Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol (2000) 1.38

A prospective randomized comparison of fine needle aspiration biopsy and fibreoptic bronchoscopy in the investigation of peripheral pulmonary opacities. Respir Med (1989) 1.38

Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol (1998) 1.38

Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis. Br J Rheumatol (1989) 1.37

[Pseudogout in 3 patients with presumed therapy-resistant rheumatoid arthritis]. Ned Tijdschr Geneeskd (2005) 1.37

Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med (1999) 1.37

The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.36

NF-kappa B regulation by I kappa B kinase in primary fibroblast-like synoviocytes. J Immunol (1999) 1.36

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis (2009) 1.34

Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol (1997) 1.34